Novartis has sued India's Cipla for infringing patents on respiratory drug Onbrez, after Cipla launched a generic In New Delhi in October.
Cipla claimed an "urgent unmet need" for the drug in India, however Novartis claims there is no shortage of Onbrez.
Onbrez is used to treat chronic obstructive pulmonary disease, and has patent protection until 2020. Novartis said it had planned to partner with generic drugmaker Lupin to sell the drug in India.
Read the Reuters article